GBT - グロ―バル・ブラッド・セラピュ―ティクス (Global Blood Therapeutics Inc.) グロ―バル・ブラッド・セラピュ―ティクス

 GBTのチャート


 GBTの企業情報

symbol GBT
会社名 Global Blood Therapeutics Inc (グロ―バル・ブラッド・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 グローバル・ブラッド・セラピューティクス(Global Blood Therapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社は、血液ベースの障害を治療するための治療薬の発見・開発・商業化に従事する。同社は鎌状赤血球症(SCD)の経口一日1回治療薬として、初期製品候補であるGBT440を開発している。同社は成人および青年期のSCD患者のGBT440の第III相臨床試験において、SCDのGBT440を評価する。GBT440は、RBC鎌状赤血球の根底にある機構である異常なヘモグロビン重合を阻害する。また、遺伝性血管浮腫(HAE)を対象としたその他の研究開発活動を行う。GBT440は、ヘモグロビンのアルファ鎖に結合することにより、ヘモグロビンの酸素に対する親和性を増加させる治験薬である。GBT440は鎌状赤血球ヘモグロビン(HbS)を酸素化状態で保持し、重合に関与しないことが観察されている。   グロ―バル・ブラッド・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、血液疾患に関する医薬品の発見、開発、商業化に従事する。薬剤候補に鎌状赤血球病(SCD)予防薬「GBT440」があり、1日1回の経口投与で治療する。激痛や多臓器損傷をもたらすSCDに焦点を当て、赤血球のメカニズムを考慮した治療薬を開発する。本社はカリフォルニア州。   
本社所在地 171 Oyster Point Boulevard Suite 300 South San Francisco CA 94080 USA
代表者氏名 Ted W. Love テッド・W・ラブ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-741-7700
設立年月日 40575
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 148人
url www.globalbloodtx.com
nasdaq_url https://www.nasdaq.com/symbol/gbt
adr_tso
EBITDA EBITDA(百万ドル) -153.88500
終値(lastsale) 35.5
時価総額(marketcap) 1847891937
時価総額 時価総額(百万ドル) 1968.135
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1505.651
当期純利益 当期純利益(百万ドル) -151.73300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Global Blood Therapeutics Inc revenues was not reported. Net loss increased 74% to $81.9M. Higher net loss reflects Research and Development Expense increase of 66% to $54.8M (expense) Stock-based Compensation in SGA increase from $2.7M to $8.8M (expense) General and administrative increase of 50% to $14.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.15 to -$1.65.

 GBTのテクニカル分析


 GBTのニュース

   GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi  2021/03/16 09:19:00 Benzinga
Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle …
   RBC Capital Stick to Their Buy Rating for Global Blood Therapeutics By Investing.com  2021/02/26 01:46:49 Investing.com
RBC Capital Stick to Their Buy Rating for Global Blood Therapeutics
   H.C. Wainwright Stick to Their Buy Rating for Global Blood Therapeutics By Investing.com  2021/02/25 11:25:42 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Global Blood Therapeutics
   Oppenheimer Stick to Their Buy Rating for Global Blood Therapeutics By Investing.com  2021/01/18 23:05:01 Investing.com
Oppenheimer Stick to Their Buy Rating for Global Blood Therapeutics
   pre-filled saline syringes market Top Players- BD, Cardinal Health, MedXL Inc., Guerbet Group, Sterisets Medical Products, DBM  2020/12/31 07:56:22 OpenPR
The global pre-filled saline syringes market accounted to US$ 402.5 Mn in 2018 and is expected to grow at a CAGR of 7.2% during the forecast period 2019 - 2027, to account to US$ 744.4 Mn by 2027. The Asia Pacific
   GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi  2021/03/16 09:19:00 Benzinga
Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle …
   RBC Capital Stick to Their Buy Rating for Global Blood Therapeutics By Investing.com  2021/02/26 01:46:49 Investing.com
RBC Capital Stick to Their Buy Rating for Global Blood Therapeutics
   H.C. Wainwright Stick to Their Buy Rating for Global Blood Therapeutics By Investing.com  2021/02/25 11:25:42 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Global Blood Therapeutics
   Oppenheimer Stick to Their Buy Rating for Global Blood Therapeutics By Investing.com  2021/01/18 23:05:01 Investing.com
Oppenheimer Stick to Their Buy Rating for Global Blood Therapeutics
   pre-filled saline syringes market Top Players- BD, Cardinal Health, MedXL Inc., Guerbet Group, Sterisets Medical Products, DBM  2020/12/31 07:56:22 OpenPR
The global pre-filled saline syringes market accounted to US$ 402.5 Mn in 2018 and is expected to grow at a CAGR of 7.2% during the forecast period 2019 - 2027, to account to US$ 744.4 Mn by 2027. The Asia Pacific
   pre-filled saline syringes market Top Players- BD, Cardinal Health, MedXL Inc., Guerbet Group, Sterisets Medical Products, DBM  2020/12/31 07:56:22 OpenPR
The global pre-filled saline syringes market accounted to US$ 402.5 Mn in 2018 and is expected to grow at a CAGR of 7.2% during the forecast period 2019 - 2027, to account to US$ 744.4 Mn by 2027. The Asia Pacific
   Morgan Stanley Stick to Their Hold Rating for Global Blood Therapeutics  2020/12/16 20:36:09 Investing.com
Morgan Stanley Stick to Their Hold Rating for Global Blood Therapeutics
   Global Blood Therapeutics recruits a CHOP sickle cell expert as R&D chief; Catalent plucks Janssen vet to head new clinical packaging facility  2020/12/11 16:54:41 Endpoints News
As a kid, Kim Smith-Whitley picked up injured animals from Rock Creek Park and biked them home in cages she built with her grandfather. They were simple things but crafty, wire mesh stitched over a base invented from whatever was around, and they wouldn’t hold the animals for long. While
   Wedbush Stick to Their Buy Rating for Global Blood Therapeutics  2020/12/11 11:26:08 Investing.com
Wedbush Stick to Their Buy Rating for Global Blood Therapeutics
   US FDA Approves Guerbet's Optiray® (Ioversol Injection) Imaging Bulk Package  2020/12/03 23:00:00 PR Newswire
PRINCETON, N.J., Dec. 3, 2020 /PRNewswire/ -- Guerbet (GBT), a global leader in medical imaging, announced today that it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) in the United States, as well as FDA clearance of…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 グロ―バル・ブラッド・セラピュ―ティクス GBT Global Blood Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)